MarketPulse

Phase 3 clinical trial

24 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Relay Therapeutics to Report 2025 Results Ahead of Phase 3 Pipeline Milestones

Relay Therapeutics reports 2025 results February 26, highlighting progress on lead drug zovegalisib advancing through Phase 3 trials with FDA Breakthrough Therapy Designation.
RLAYPhase 3 clinical trialFDA Breakthrough Therapy Designation
GlobeNewswire Inc.GlobeNewswire Inc.··Na

4DMT to Present Pipeline Progress at Three Major Healthcare Conferences

4DMT will present pipeline progress at three major healthcare conferences in March 2026, showcasing late-stage programs including 4D-150 for retinal disease and 4D-710 for cystic fibrosis.
FDMTPhase 3 clinical trialinvestor conference
GlobeNewswire Inc.GlobeNewswire Inc.··Eyepoint, Inc.

EyePoint Pharmaceuticals Names Veteran Ophthalmology Executive Campbell as CCO

EyePoint Pharmaceuticals appoints Michael Campbell as Chief Commercial Officer. The ophthalmology veteran brings 30+ years of experience to lead commercial strategy for DURAVYU ahead of 2026 clinical data.
EYPTPhase 3 clinical trialophthalmology
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Ocular Therapeutix to Release SOL-1 Phase 3 Results for Wet AMD Treatment

Ocular Therapeutix announces Phase 3 results for SOL-1 wet AMD treatment on February 17, 2026. AXPAXLI data presentation follows at Macula Society Annual Meeting.
OCULPhase 3 clinical trialbiopharmaceutical